Valiant Laboratories

Valiant Laboratories Long-term Debt

The Long-Term Debt of Valiant Laboratories (VALIANTLAB.NS) as of Nov 4, 2026 is 280.93 M INR. In the previous year, Long-Term Debt was 1.04 B INR — a change of -73.08% (lower).

Long-term Debt

280.93 MINR

YoY

-73.08%

Last updated:

Long-Term Debt of Valiant Laboratories is 2026 280.93 M INR. Long-Term Debt of Valiant Laboratories was 2025 1.04 B INR. It decreases by -73.08% lower compared to the previous year.

The Valiant Laboratories Long-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Long-term Debt
Date
Long-term Debt
Jan 1, 2022
594.00 M INR
Jan 1, 2023
594.00 M INR
Jan 1, 2024
746.63 M INR
Jan 1, 2025
1.04 B INR
Jan 1, 2026
280.93 M INR
The Valiant Laboratories Long-term Debt history
YEARLong-term DebtYoY
280.93 MINR-73.08%
1.04 BINR+39.76%
746.63 MINR+25.69%
594.00 MINR+0.00%
594.00 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valiant Laboratories Stock analysis

What does Valiant Laboratories do? Valiant Laboratories Ltd manufactures paracetamol API/bulk drug for pharmaceutical applications, targeting medical conditions such as headache, muscle ache, arthritis, back ache, toothache, cold, and fever. The company operates a single manufacturing facility at Tarapur industrial estate, approximately 150 km from Nhava Sheva Port (JNPT), producing specialty chemicals and pharma intermediates for domestic and international markets. Its subsidiary, VALIANT ADVANCED SCIENCES PRIVATE LIMITED, supports the company's operations in the pharmaceutical sector. The firm's primary revenue comes from selling paracetamol API and specialty chemicals to pharmaceutical companies and distributors globally. Manufacturing focuses on high-demand applications like pain relief and fever treatment, with products distributed across India and abroad. The company leverages its Tarapur facility's proximity to Nhava Sheva Port for efficient export logistics. Valiant Laboratories Ltd serves the pharmaceutical industry by supplying essential active ingredients, particularly paracetamol, which is widely used in over-the-counter medications. The company's manufacturing capabilities for specialty chemicals and pharma intermediates cater to both domestic and international clients seeking reliable API sources. Its single-location production model ensures focused resource allocation for consistent output quality. Valiant Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Valiant Laboratories stock

Long-Term Debt of Valiant Laboratories is 280.93 M INR in 2026.

Long-Term Debt of Valiant Laboratories changed from 1.04 B INR to 280.93 M INR, representing a -73.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt Valiant Laboratories since 2006 – with annual values, charts, and detailed analysis.

Long-term debt represents obligations due after one year. It is a key component of a company's capital structure and leverage.

Long-Term Debt's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Debt's Valiant Laboratories historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Valiant Laboratories

All Key Metrics — Valiant Laboratories